Rituximab

Rituximab is indicated for the treatment of:

Non-Hodgkin’s Lymphoma

– patients with low-grade or follicular B-cell non-Hodgkin’s lymphoma, CD20-positive, relapsed or resistant to chemotherapy
– patients with diffuse large B-cell non-Hodgkin’s lymphoma, CD20 positive, in combination with CHOP chemotherapy
– patients with B-cell non-Hodgkin’s lymphoma, follicular, CD20 positive, not previously treated, in combination with chemotherapy
– patients with follicular lymphoma, as maintenance therapy following response to induction treatment.

Rheumatoid Arthritis
Rituximab, in combination with methotrexate, is indicated for the treatment of adult patients with active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitor therapies.

Chronic Lymphocytic Leukemia
Rituximab, in combination with chemotherapy, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) and relapsed/refractory to treatment.

Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
Rituximab, in combination with glucocorticoids, is indicated for the treatment of the following severe active vasculitides: granulomatosis with polyangiitis (GPA, also known as Wegener’s Granulomatosis) and microscopic polyangiitis (MPA).